Drug Approval | November 11, 2022
Sanofi, GSK’s next-generation COVID-19 booster vaccine approved by the European Commission
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
The company is making its entry into the Hyderabad market through its unique asset-light business model
The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)
R&D center would be doing a lot of new product generation projects, process optimization, scale-up and product life cycle management work, full synthetic labs, the kilo labs, the process safety labs, and the population lab
Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
Saroglitazar Mg is an investigational compound in the USA/EU, undergoing Phase 2b/3 clinical trials in patients with Primary Biliary Cholangitis and Phase 2b in patients with Non- alcoholic Steatohepatitis
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
The JUMP-CP Consortium’s aim is to validate and scale up image-based drug discovery strategies by creating the world’s largest public cell imaging data set
On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions
CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus
Subscribe To Our Newsletter & Stay Updated
